PMID- 26704150
OWN - NLM
STAT- MEDLINE
DCOM- 20161028
LR  - 20231019
IS  - 1097-0193 (Electronic)
IS  - 1065-9471 (Print)
IS  - 1065-9471 (Linking)
VI  - 37
IP  - 3
DP  - 2016 Mar
TI  - Dopaminergic system and dream recall: An MRI study in Parkinson's disease 
      patients.
PG  - 1136-47
LID - 10.1002/hbm.23095 [doi]
AB  - We investigated the role of the dopamine system [i.e., subcortical-medial 
      prefrontal cortex (mPFC) network] in dreaming, by studying patients with 
      Parkinson's Disease (PD) as a model of altered dopaminergic transmission. 
      Subcortical volumes and cortical thickness were extracted by 3T-MR images of 27 
      PD patients and 27 age-matched controls, who were asked to fill out a dream diary 
      upon morning awakening for one week. PD patients do not substantially differ from 
      healthy controls with respect to the sleep, dream, and neuroanatomical measures. 
      Multivariate correlational analyses in PD patients show that dopamine agonist 
      dosage is associated to qualitatively impoverished dreams, as expressed by lower 
      bizarreness and lower emotional load values. Visual vividness (VV) of their dream 
      reports positively correlates with volumes of both the amygdalae and with 
      thickness of the left mPFC. Emotional load also positively correlates with 
      hippocampal volume. Beside the replication of our previous finding on the role of 
      subcortical nuclei in dreaming experience of healthy subjects, this represents 
      the first evidence of a specific role of the amygdala-mPFC dopaminergic network 
      system in dream recall. The association in PD patients between higher dopamine 
      agonist dosages and impoverished dream reports, however, and the significant 
      correlations between VV and mesolimbic regions, however, provide an empirical 
      support to the hypothesis that a dopamine network plays a key role in dream 
      generation. The causal relation is however precluded by the intrinsic limitation 
      of assuming the dopamine agonist dosage as a measure of the hypodopaminergic 
      state in PD. Periodicals, Inc.
CI  - (c) 2015 Wiley Periodicals, Inc.
FAU - De Gennaro, Luigi
AU  - De Gennaro L
AD  - Department of Psychology, University of Rome "Sapienza,", Rome, Italy.
FAU - Lanteri, Olimpia
AU  - Lanteri O
AD  - Department of Psychology, University of Rome "Sapienza,", Rome, Italy.
FAU - Piras, Fabrizio
AU  - Piras F
AD  - Department of Clinical and Behavioral Neurology, Santa Lucia Foundation, Rome, 
      Italy.
AD  - Centro Studi e Ricerche Enrico Fermi, Compendio del Viminale, Rome, Italy.
FAU - Scarpelli, Serena
AU  - Scarpelli S
AD  - Department of Psychology, University of Rome "Sapienza,", Rome, Italy.
FAU - Assogna, Francesca
AU  - Assogna F
AD  - Department of Clinical and Behavioral Neurology, Santa Lucia Foundation, Rome, 
      Italy.
FAU - Ferrara, Michele
AU  - Ferrara M
AD  - Department of Life, Health and Environmental Sciences, University of L'aquila, 
      Italy.
FAU - Caltagirone, Carlo
AU  - Caltagirone C
AD  - Department of Clinical and Behavioral Neurology, Santa Lucia Foundation, Rome, 
      Italy.
AD  - Department of Neuroscience, University of Tor Vergata, Rome, Italy.
FAU - Spalletta, Gianfranco
AU  - Spalletta G
AD  - Department of Clinical and Behavioral Neurology, Santa Lucia Foundation, Rome, 
      Italy.
AD  - Menninger Department of Psychiatry and Behavioral Sciences, Baylor College of 
      Medicine, Houston, Texas.
LA  - eng
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
DEP - 20151224
PL  - United States
TA  - Hum Brain Mapp
JT  - Human brain mapping
JID - 9419065
RN  - 0 (Antiparkinson Agents)
RN  - 0 (Dopamine Agonists)
SB  - IM
MH  - Adult
MH  - Aged
MH  - Antiparkinson Agents/adverse effects/therapeutic use
MH  - Brain/*drug effects/pathology
MH  - Dopamine Agonists/adverse effects/*therapeutic use
MH  - Dreams/*drug effects/physiology/psychology
MH  - Emotions/drug effects/physiology
MH  - Female
MH  - Humans
MH  - Magnetic Resonance Imaging
MH  - Male
MH  - Mental Recall/*drug effects/physiology
MH  - Middle Aged
MH  - Neuropsychological Tests
MH  - Organ Size
MH  - Parkinson Disease/*drug therapy/pathology/*psychology
MH  - Sleep/drug effects/physiology
PMC - PMC6867535
OTO - NOTNLM
OT  - MRI
OT  - VBM
OT  - amygdala
OT  - dopamine
OT  - dream recall
OT  - dreaming
OT  - hippocampus
OT  - medial prefrontal cortex
OT  - mesolimbic dopaminergic system
OT  - sleep
EDAT- 2015/12/26 06:00
MHDA- 2016/11/01 06:00
PMCR- 2015/12/24
CRDT- 2015/12/26 06:00
PHST- 2015/04/20 00:00 [received]
PHST- 2015/12/04 00:00 [revised]
PHST- 2015/12/05 00:00 [accepted]
PHST- 2015/12/26 06:00 [entrez]
PHST- 2015/12/26 06:00 [pubmed]
PHST- 2016/11/01 06:00 [medline]
PHST- 2015/12/24 00:00 [pmc-release]
AID - HBM23095 [pii]
AID - 10.1002/hbm.23095 [doi]
PST - ppublish
SO  - Hum Brain Mapp. 2016 Mar;37(3):1136-47. doi: 10.1002/hbm.23095. Epub 2015 Dec 24.